TheraRadar
← Back
Data updated: Jul 17, 2026

BECTON DICKINSON

Specialty
DermatologyMetabolic Execution: Excellent

BECTON DICKINSON is a specialty pharmaceutical company focused on Dermatology, Metabolic.

1976
Since
10
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
6 Small Molecules

BECTON DICKINSON at a Glance

  • Strong track record with 100% execution quality across 6 trials
  • Fast trial execution (3 months median completion)

BECTON DICKINSON's Key Drugs

BECTON DICKINSON's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BECTON DICKINSON's Recent FDA Approvals

New NDA/BLA approvals for BECTON DICKINSON over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BECTON DICKINSON's Therapeutic Areas

BECTON DICKINSON's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Metabolic, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 50%
0 drugs Phase 2: 2
Metabolic 50%
0 drugs Phase 1: 4

BECTON DICKINSON's Top Competitors

BECTON DICKINSON's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, KING PHARMS LLC, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Eli Lilly big-pharma
Metabolic, Dermatology
KING PHARMS LLC big-pharma
Dermatology, Metabolic
PHARMACIA AND UPJOHN big-pharma
Dermatology, Metabolic
LEO PHARMA AS big-pharma
Dermatology, Metabolic
Pfizer big-pharma
Dermatology

BECTON DICKINSON Pipeline Snapshot

BECTON DICKINSON has 6 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 2 Phase 2 and 4 Phase 1.

0
Phase 3
2
Phase 2
4
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 3 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges